enVVeno Medical
NVNO
9 hedge funds and large institutions have $261K invested in enVVeno Medical in 2019 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 0 closing their positions.
200% more funds holding
Funds holding: 3 → 9 (+6)
9% more capital invested
Capital invested by funds: $240K → $261K (+$21K)
0% more ownership
Funds ownership: 0% → 0% (+0%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MA
MYDA Advisors
Woodmere,
New York
|
+$60.9K |
| 2 |
Jane Street
New York
|
+$55.6K |
| 3 |
GIA
Gladstone Institutional Advisory
Palm Beach Gardens,
Florida
|
+$20K |
| 4 |
AG
Advisor Group
Phoenix,
Arizona
|
+$14.8K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$5.22K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$86.9K |
NVNO Hedge Fund Activity: Q3 2019 in Review
9 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in enVVeno Medical (NVNO) for Q3 2019, worth a combined $261K — up 8.8% from $240K a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new NVNO positions and 0 closed out — a net gain of 6 holders — while 1 added to existing stakes and 1 trimmed.
The largest buyer was MYDA Advisors, opening a new position worth an estimated $60.9K. The largest seller was Vanguard Group, cutting an estimated $86.9K.
- 9 institutional investors held enVVeno Medical (NVNO) as of Q3 2019, up from 3 in Q2 2019.
- Funds reported $261K of enVVeno Medical stock for Q3 2019, up 8.8% quarter-over-quarter.
- 6 funds opened new enVVeno Medical positions in Q3 2019 and 0 closed out, a net change of +6 holders.
- The largest enVVeno Medical buyer in Q3 2019 was MYDA Advisors, an estimated $60.9K added.
- The largest enVVeno Medical seller in Q3 2019 was Vanguard Group, an estimated $86.9K sold.
Based on aggregated 13F filings for Q3 2019.